Incruse Ellipta (Umeclidinium Bromide)

Umeclidinium bromide works by selectively blocking muscarinic M3 receptors on airway smooth‑muscle cells. This antagonism prevents acetylcholine‑induced muscle contraction, leading to sustained bronchodilation, lower airway resistance, and improved airflow in patients with COPD.

The prescribed dose of Incruse Ellipta is determined by the treating physician. Typically, one inhalation of the 62.5 µg dry‑powder inhaler is taken once daily, but the exact regimen should follow the prescriber’s instructions and the product label.

The safety of Incruse Ellipta in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the prescriber in consultation with the patient.

To order Incruse Ellipta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Incruse Ellipta is a long‑acting muscarinic antagonist (LAMA) that provides once‑daily bronchodilation. Compared with short‑acting agents or combination inhalers, it offers sustained airway opening with a convenient dosing schedule, but it does not contain a corticosteroid component, so some patients may require additional therapy for inflammation control.

Incruse Ellipta should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not expose the inhaler to extreme heat or humidity, as this may affect the powder’s integrity and dose consistency.

Incruse Ellipta is a dry‑powder inhaler. The patient opens the device, exhales fully away from the inhaler, places the mouthpiece in the mouth, and inhales forcefully and deeply to ensure the powder is delivered to the lungs. The inhaler is then closed to protect the dose.

Serious risks include paradoxical bronchospasm, severe allergic reactions such as angioedema, urinary retention, and narrow‑angle glaucoma exacerbation. Patients should seek immediate medical attention if they experience sudden breathing difficulty, swelling of the face or throat, or inability to urinate.

Incruse Ellipta should be avoided in patients with known hypersensitivity to umeclidinium or any excipients, those with narrow‑angle glaucoma, uncontrolled urinary retention, or severe hepatic impairment. It is also contraindicated in individuals for whom a long‑acting anticholinergic is medically inappropriate.